Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Invasion and Metastasis of Colon Cancer
share announcement

Invasion and Metastasis of Colon Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 7303

Special Issue Editors

Dr. Océane Martin

E-Mail Website
Guest Editor
INSERM U1312 BRIC Bordeaux Institute of Oncology, Université de Bordeaux, 33077 Bordeaux, France
Interests: cancer biology; CRC; brain tumors
Dr. Descarpentrie Jean

E-Mail Website
Guest Editor
Reprogramming Tumor Activity and Associated MicroEnvironment (RYTME), Bordeaux Institute of Oncology (BRIC)-UMR1312 Inserm, B2 Ouest, Allée Geoffroy St Hilaire CS50023, 33615 Pessac, France
Interests: cancer biology; CRC; metastasis
Prof. Dr. Antonio V. Sterpetti

E-Mail Website
Guest Editor
Department of Surgery “Pietro Valdoni”, University of Rome, 00161 Rome, Italy
Interests: inflammation and cancer; aging and cancer; robotic surgery for colorectal cancer; screening for colorectal cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Colorectal cancer (CRC) commonly metastasizes; approximately 50% of patients with CRC develop metastasis during their history. In decreasing order, liver, lung, peritoneum, lymph nodes, bone, brain, and even thyroid are the most common sites of CRC metastases. The metastasis process is characterized by invasion, intravasation, circulation, extravasation, and colonization steps. During each step, some molecular and physiological processes take place, such as the transition between epithelial and mesenchymal phenotypes (EMT and MET), circulating tumor cells, tumor dormancy, microenvironment rearrangement and pre-metastatic niches, cancer stem cells, genomic instability, epigenetic modification and immunosuppression. Despite the advancements in therapy and surgery, the 5-year overall survival (OS) rate of patients with CRC metastasis is below 40%.

We welcome contributions in the form of original research papers, brief research reports, systematic reviews, reviews, mini reviews, policy and practice reviews, methods, hypotheses and theories, perspectives, clinical trials, case reports, data reports, brief research reports, general commentaries, opinions, technology and code that cover the following themes:

  • Mechanistic insights in metastasis-related CRC, such as the identification of dysregulated molecular and physiological processes;
  • Novel therapeutic approaches targeting metastasis from CRC;
  • Preclinical experimental models studying metastasis from CRC;
  • Translational studies related to metastasis from CRC;
  • Novel methodological approaches and advances in software tools improving the phenotypic and molecular characterization of metastasis from CRC.

Dr. Océane Martin
Dr. Descarpentrie Jean
Prof. Dr. Antonio V. Sterpetti 
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • microenvironment
  • metastasis
  • distant organs
  • circulating cells
  • dormancy
  • metastatic niche
  • stem cells

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 2060 KiB  
Review
KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies
by Alessandro Ottaiano, Francesco Sabbatino, Francesco Perri, Marco Cascella, Roberto Sirica, Renato Patrone, Maurizio Capuozzo, Giovanni Savarese, Monica Ianniello, Nadia Petrillo, Luisa Circelli, Vincenza Granata, Massimiliano Berretta, Mariachiara Santorsola and Guglielmo Nasti
Cancers 2023, 15(14), 3579; https://doi.org/10.3390/cancers15143579 - 12 Jul 2023
Cited by 6 | Viewed by 1820
Abstract
KRAS is frequently mutated in tumors. It is mutated in approximately 30% of all cancer cases and in nearly 50% of cases of metastatic colorectal cancer (CRC), which is the third leading cause of cancer-related deaths worldwide. Recent advancements in understanding CRC biology [...] Read more.
KRAS is frequently mutated in tumors. It is mutated in approximately 30% of all cancer cases and in nearly 50% of cases of metastatic colorectal cancer (CRC), which is the third leading cause of cancer-related deaths worldwide. Recent advancements in understanding CRC biology and genetics have highlighted the significance of KRAS mutations in the progression of CRC. The KRAS gene encodes a small GTPase (Guanosine TriPhosphatases) that plays a key role in signaling pathways associated with important proteins involved in amplifying growth factor and receptor signals. Mutations in KRAS are frequently observed in codons 12 and 13, and these mutations have oncogenic properties. Abnormal activation of KRAS proteins strongly stimulates signals associated with various cancer-related processes in CRC, including cell proliferation, migration and neoangiogenesis. In this review, we explore the distinct prognostic implications of KRAS mutations. Specifically, the KRAS p.G12C mutation is associated with a worse prognosis in metastatic CRC. The correlation between structure, conformation and mutations is visually presented to emphasize how alterations in individual amino acids at the same position in a single protein can unexpectedly exhibit complex involvement in cancer. Last, KRAS p.G12C is discussed as an emerging and promising therapeutic target in metastatic CRC, providing a concise overview of available clinical data regarding the use of new inhibitors. Full article
(This article belongs to the Special Issue Invasion and Metastasis of Colon Cancer)
►▼ Show Figures

Figure 1

36 pages, 2342 KiB  
Review
Experimental Murine Models for Colorectal Cancer Research
by Íris Neto, João Rocha, Maria Manuela Gaspar and Catarina P. Reis
Cancers 2023, 15(9), 2570; https://doi.org/10.3390/cancers15092570 - 30 Apr 2023
Cited by 5 | Viewed by 4702
Abstract
Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and in both sexes. Numerous animal models for CRC have been established to study its biology, namely carcinogen-induced models (CIMs) and genetically engineered mouse models (GEMMs). CIMs are valuable for assessing colitis-related carcinogenesis [...] Read more.
Colorectal cancer (CRC) is the third most prevalent malignancy worldwide and in both sexes. Numerous animal models for CRC have been established to study its biology, namely carcinogen-induced models (CIMs) and genetically engineered mouse models (GEMMs). CIMs are valuable for assessing colitis-related carcinogenesis and studying chemoprevention. On the other hand, CRC GEMMs have proven to be useful for evaluating the tumor microenvironment and systemic immune responses, which have contributed to the discovery of novel therapeutic approaches. Although metastatic disease can be induced by orthotopic injection of CRC cell lines, the resulting models are not representative of the full genetic diversity of the disease due to the limited number of cell lines suitable for this purpose. On the other hand, patient-derived xenografts (PDX) are the most reliable for preclinical drug development due to their ability to retain pathological and molecular characteristics. In this review, the authors discuss the various murine CRC models with a focus on their clinical relevance, benefits, and drawbacks. From all models discussed, murine CRC models will continue to be an important tool in advancing our understanding and treatment of this disease, but additional research is required to find a model that can correctly reflect the pathophysiology of CRC. Full article
(This article belongs to the Special Issue Invasion and Metastasis of Colon Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop